Skip to main content
. 2021 Oct 4;20:128. doi: 10.1186/s12943-021-01422-7

Table 5.

Development history and application status of KRAS-G12C inhibitors

Name Application date Institutions Structure Status Reference/ trial number
1_AM August 2017 Dana-Farber Cancer Institute graphic file with name 12943_2021_1422_Figa_HTML.gif Preclinical [169]
Adagrasib October 2019 Mirati graphic file with name 12943_2021_1422_Figb_HTML.gif Clinical (approved)

[16]

NCT04685135; NCT03785249; NCT04330664; NCT04793958
ARS-853 January 2016 Memorial Sloan Kettering Cancer Center graphic file with name 12943_2021_1422_Figc_HTML.gif Preclinical [170]
ARS-1620 January 2018 Wellspring Biosciences graphic file with name 12943_2021_1422_Figd_HTML.gif Preclinical [171]
Compound 12 November 2013 University of California graphic file with name 12943_2021_1422_Fige_HTML.gif Preclinical [172]
D-1553 October 2020 InventisBio Structure not disclosed Clinical (recruiting) NCT04585035
GDC-6036 June 2020 Genentech Structure not disclosed Clinical (recruiting) NCT04449874
JNJ-74699157 July 2019 Araxes/J&J Structure not disclosed Clinical (terminated) NCT04006301
LY3499446 November 2019 Eli Lilly Structure not disclosed Clinical (terminated) NCT04165031
Sotorasib October 2019 Amgen graphic file with name 12943_2021_1422_Figf_HTML.gif Clinical (approved)

[15]

NCT04303780; NCT03600883; NCT04613596